J
Jacobio Pharmaceuticals Group Co., Ltd. (JBPHF)
PNK – Real vaqt narxi. Valyuta: USD
0.68
0.00 (0.00%)
Yopilishda: Sep 10, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
PNK – Real vaqt narxi. Valyuta: USD
0.68
0.00 (0.00%)
Yopilishda: Sep 10, 2026, 4:00 PM EDT
Jacobio Pharmaceuticals Group Co., Ltd., investitsiya holding kompaniyasi, Xitoy Xalq Respublikasida onkologik terapiyalarni o'z ichida kashf qilish va rivojlantirish bilan shug'ullanadi. Kompaniya sitneprotafib (JAB-3312)ni ishlab chiqadi, bu esa kichik hujayrali bo'lmagan o'pka saratoni (NSCLC) uchun III bosqich sinovlarida bo'lgan og'zaki allosterik SHP2 inhibitoridir; glecirasib (JAB-21822), NSCLC, ko'p o'simtali savat va kolorektal saraton uchun II bosqich sinovlarida bo'lgan KRAS G12C allosterik inhibitoridir; JAB-8263, qattiq o'smalar va gematologik malignansiyalar uchun IIa bosqich sinovlarida bo'lgan BET inhibitoridir; JAB-BX102, CD73 ga qarshi insonlashtirilgan monoklonal antiteladir, bu esa I/IIa bosqich sinovlarida; JAB-2485, qattiq o'smalar uchun I/IIa bosqich sinovlarida bo'lgan yuqori selektiv Aurora Kinase A (AURKA) inhibitoridir; JAB-23E73, KRAS-mutatsiyali PDAC, CRC, NSCLC va qattiq o'smalar uchun I bosqich sinovlarida bo'lgan og'zaki kichik molekulali pan-KRAS inhibitoridir; va JAB-30355, mahalliy rivojlangan yoki metastatik qattiq o'smalarga chalingan bemorlarni davolash uchun I bosqich sinovlarida bo'lgan bioavailable kichik molekulali p53 reaktivatoridir. Kompaniya shuningdek, qattiq o'smalar uchun IND-tayyorlovchi nomzodlarni, jumladan JAB-BX467, JAB-BX600 va JAB-BX700 ni ishlab chiqmoqda. Kompaniya JAB-23E73 ni ishlab chiqish va tijoratlashtirish uchun AstraZeneca AB bilan hamkorlik shartnomasiga ega. Jacobio Pharmaceuticals Group Co., Ltd. 2015-yilda tashkil etilgan va Xitoyning Pekin shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Andrea Wang-Gillam M.D., Ph.D. | Co-CEO, Executive VP, Chief Medical Officer and Global Head of R&D |
| Dr. Haijun Wang | Senior Vice President of Information & Data Management |
| Dr. Yinxiang Wang | Founder, Co-CEO & Executive Chairman |
| Ms. Qing Xue | Joint Company Secretary |
| Ms. Tao Yang | Vice President of Human Resources |
| Ms. Xiaojie Wang | Executive Director & President of Administration |
There is no data to display
| Ms. Yanping Wang |
| Executive Vice President of Non-Clinical R&D |
| Ms. Yuli Ding | Executive Vice President of Clinical Development |
| Ms. Yunyan Hu | Executive VP & Executive Director |